XXXX - @entity4334 Analog Combination Therapy Is Effective in Preventing Recurrent @entity1956 After Liver Transplantation.

@entity1 @entity97 @entity23109 @entity1956 @entity8742 @entity4334
BACKGROUND: @entity1956 immune globulin (HBIg) in combination with a nucleos(t)ide analog is the mainstay of prophylactic regimen to prevent recurrence of @entity1956 following orthotopic liver transplantation (OLT). HBIg therapy is costly and inconvenient for the @entity1 . There is a growing experience converting HBIg/nucleos(t)ide to combination @entity4334 / @entity8742 analogs from. METHODS: Twenty-six @entity1 that underwent OLT between March 2001 and July 2011 who had received at least 12  months of HBIg and single nucleos(t)ide were enrolled. HBsAg and @entity97 DNA were undetectable, and anti-HBs were detectable at the time of switch. @entity97 DNA and @entity23109 were measured every 3  months following discontinuation of HBIg and addition of nucleos(t)ide. RESULTS: @entity1 included 23 Asians/3 Caucasian, 21 males/5 females. Mean time of conversion from HBIg/nucleos(t)ide to @entity8742 / @entity4334 combination was 77.5 (range 11-132) months after OLT. Mean duration of follow-up after conversion was 31.9 (range 14-70) months. All @entity1 had undetectable @entity97 DNA, and 24 @entity1 remained HBsAg negative during follow-up. Two @entity1 recurred 7 and 9  months later, respectively, with detectable HBsAg. Both @entity1 continued to have undetectable @entity97 DNA and normal ALT. HBsAg was neutralized by reinfusion of HBIg. CONCLUSION: @entity8742 / @entity4334 combination is an effective alternative to HBIg/nucleos(t)ide to prevent recurrence of @entity1956 after OLT.
